The team of researchers followed up older people from the Sydney Memory and Aging Study, including healthy people and people with mild cognitive impairment, over two years, and measured their apolipoprotein levels. They found that the levels of the proteins were altered in people with cognitive impairment, and that, in people with normal cognition, lower levels of ApoA1, ApoH and ApoJ (clusterin) predicted a decline in cognitive impairment, the early stages of Alzheimer's disease. The results were published in PLoS One.
No comments:
Post a Comment